Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma

Biological Chemistry

Volumn 387, Issue 8, 2006, Pages 1121-1128

  Dorn, Julia ^a   Harbeck, Nadia ^a   Kates, Ronald ^a   Magdolen, Viktor ^a   Grass, Linda ^b   Soosaipillai, Antoninus ^b   Schmalfeldt, Barbara ^a   Diamandis, Eleftherios P ^b   Schmitt, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Ovarian cancer; PAI 1; Plasminogen activator; Plasminogen activator inhibitor type 1; Proteolytic factors; Tissue kallikreins; uPA; Urokinase

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; TISSUE KALLIKREIN; TISSUE KALLIKREIN 10; TISSUE KALLIKREIN 11; TISSUE KALLIKREIN 5; TISSUE KALLIKREIN 6; TISSUE KALLIKREIN 7; TISSUE KALLIKREIN 8; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CANCER GRADING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE KALLIKREINS; URINARY PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 33746920389     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.138     Document Type: Article

References (50)

1. Bast, R.C. Jr., Lilja, H., Urban, N., Rimm, D.L., Fritsche, H., Gray, J., Veltri, R., Klee, G., Allen, A., Kim, N., Gutman, S., Rubin, M.A., and Hruszkewycz, A. (2005). Translational crossroads for biomarkers. Clin. Cancer Res. 11, 6103-6108.
2. Borgfeldt, C., Hansson, S.R., Gustavsson, B., Masback, A., and Casslen, B. (2001). Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int. J. Cancer 92, 497-502.
3. Borgono, C.A. and Diamandis, E.P. (2004).The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
4. Borgono, C.A., Grass, L., Soosaipillai, A., Yousef, G.M., Petraki, C.D., Howarth, D.H., Fracchioli, S., Katsaros, D., Diamandis, E.P. (2001). Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res. 63, 9032-9041.
5. Borgono, C.A., Fracchioli, S., Yousef, G.M., Rigault de la Longrais, I.A., Luo, L.Y., Soosaipillai, A., Puopolo, M., Grass, L., Scorilas, A., Diamandis, E.P., and Katsaros, D. (2003). Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int. J. Cancer 106, 605-610.
6. Borgono, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280.
7. Burke, H.B., Goodman, P.H., Rosen, D.B., Henson, D.E., Weinstein, J.N., Harrell, F.E. Jr., Marks, J.R., Winchester, D.P., and Bostwick, D.G. (1997). Artificial neural networks improve the accuracy of cancer survival prediction. Cancer 79, 857-862.
8. Cannistra, S.A. (2004). Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529.
9. Castellino, F.J. and Ploplis, V.A. (2005). Structure and function of the plasminogen/plasmin system. Thromb. Haemost. 93, 647-654.
10. Clements, J.A., Willemsen, N.M., Myers, S.A., and Dong, Y. (2004). The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41, 265-312.
11. De Laurentiis, M., de Placido, S., Bianco, A.R., Clark, G.M., and Ravdin, P.M. (1999). A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients. Clin. Cancer Res. 5, 4133-4139.
12. Diamandis, E.P., Yousef, G.M., Soosaipillai, A.R., and Bunting, P. (2000). Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin. Biochem. 33, 579-583.
13. Diamandis, E.P., Scorilas, A., Fracchioli, S., Van Gramberen, M., De Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G.M., Stenman, U.H., et al. (2003). Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 21, 1035-1043.
14. Durand, M.K., Bodker, J.S., Christensen, A., Dupont, D.M., Hansen, M., Jensen, J.K., Kjelgaard, S., Mathiasen, L., Pedersen, K.E., Skeldal, S., et al. (2004). Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb. Haemost. 91, 438-449.
15. Frederick, R., Pochet, L., Charlier, C., and Masereel, B. (2005). Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex. Curr. Med. Chem. 12, 397-417.
16. Frenette, G., Tremblay, R.R., Lazure, C., and Dube, J.Y. (1997). Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 71, 897-899.
17. Garner, E.I. (2005). Advances in the early detection of ovarian carcinoma. J. Reprod. Med. 50, 447-453.
18. Gleeson, N.C., Hill, B.J., Moscinski, L.C., Mark, J.E., Roberts, W.S., Hoffman, M-S., Fiorica, J-V., and Cavanagh, D. (1996). Urokinase plasminogen activator in ovarian cancer. Eur. J. Gynaecol. Oncol. 17, 110-113.
19. Harbeck, N., Kates, R., Ulm, K., Graeff, H., and Schmitt, M. (2000). Neural network analysis of follow-up data in primary breast cancer. Int. J. Biol. Markers 15, 116-122.
20. Jerez-Aragones, J.M., Gomez-Ruiz, J.A., Ramos-Jimenez, G., Munoz-Perez, J., and Alba-Corlejo, E. (2003). A combined neural network and decision trees model for prognosis of breast cancer relapse. Artif. Intell. Med. 27, 45-63.
21. Johann, D.J. Jr., McGuigan, M.D., Patel, A.R., Tomov, S., Ross, S., Conrads, T.P., Veenstra, T.D., Fishman, D.A., Whiteley, G.R., Petricoin, E.F. III, and Liotta, L.A. (2004). Clinical proteomics and biomarker discovery. Ann. NY Acad. Sci. 1022, 295-305.
22. Kates, R., Schmitt M., and Harbeck N. (2003) Advanced statistical methods for the definition of new staging models. Recent Results Cancer Res. 62, 101-113.
23. Kishi, T., Grass, L., Soosaipillai, A., Scorilas, A., Harbeck, N., Schmalfeldt, B., Dorn, J., Mysliwiec, M., Schmitt, M., and Diamandis, E.P. (2003). Human kallikrein 8: a novel biomarker for ovarian carcinoma. Cancer Res. 63, 2771-2774.
24. Konecny, G., Untch, M., Pihan, A., Kimmig, R., Gropp, M., Stieber, P., Hepp, H., Slamon, D., and Pegram, M. (2001). Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin. Cancer Res. 7, 1743-1749.
25. Kuhn, W., Pache, L., Schmalfeldt, B., Dettmar, P., Schmitt, M., Jänicke, F., and Graeff, H. (1994). Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol. 55, 401-409.
26. Kuhn, W., Schmalfeldt, B., Reuning, U., Pache, L., Berger, U., Ulm, K., Harbeck, N., Späthe, K., Dettmar, P., Höfler, H., et al. (1999). Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer 79, 1746-1751.
27. List, K., Jensen, O.N., Bugge, T.H., Lund, L.R., Ploug, M., Danø, K., and Behrendt, N. (2000). Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry 39, 508-515.
28. Luo, L.Y., Bunting, P., Scorilas, A., and Diamandis, E.P. (2001). Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin. Chim. Acta 306, 111-118.
29. Luo, L.Y., Katsaros, D., Scorilas, A., Fracchioli, S., Bellino, R., van Gramberen, M., de Bruijn, H., Henrik, A., Stenman, UH., Massobrio, M., et al. (2003). The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 63, 807-811.
30. Magklara, A., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G.M., Fracchioli, S., Danese, S., and Diamandis, E.P. (2001). The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin. Cancer Res. 7, 806-811.
31. Myohanen, H. and Vaheri, A. (2004). Regulation and interactions in the activation of cell-associated plasminogen. Cell. Mol. Life Sci. 61, 2840-2858.
32. Obiezu, C.V. and Diamandis, E.P. (2005). Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 224, 1-22.
33. Paliouras, M. and Diamandis, E.R (2006). The kallikrein world: an update on the human tissue kallikreins. Biol. Chem. 387, 643-652.
34. Reuning, U., Magdolen, V., Wilhelm, O., Fischer, K., Lutz, V., Graeff, H., and Schmitt, M. (1998). Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 13, 893-906.
35. Reuning, U., Magdolen, V., Hapke, S., and Schmitt, M. (2003). Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol. Chem. 384, 1119-1131.
36. Rosen, D.G., Wang, L., Atkinson, J.N., Yu, Y., Lu, K.H., Diamandis, E.P, Hellstrom, I., Mok, S.C., Liu, J., and Bast R.C. Jr. (2005). Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99, 267-277.
37. Schenone, M., Furie, B.C., and Furie, B. (2004). The blood coagulation cascade. Curr. Opin. Hematol. 11, 272-277.
38. Schmalfeldt, B., Kuhn, W., Reuning, U., Pache, L., Dettmar, P., Schmitt, M., Jänicke, F., Höfler, H., and Graeff, H. (1995). Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 55, 3958-3963.
39. Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Höfler, H., Jänicke, F., and Graeff, H. (1997). Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78, 285-296.
40. Scorilas, A., Borgono, C.A., Harbeck, N., Dorn, J., Schmalfeldt, B., Schmitt, M., and Diamandis, E.P. (2004). Human kallikrein 13 protein in ovarian cancer cytosols: a new favourable prognostic marker. J. Clin. Oncol. 22, 678-685.
41. Shi, Y. (2004). Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci. 13, 1979-1987.
42. Skrzydlewska, E., Sulkowska, M., Koda, M., and Sulkowski, S. (2005). Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J. Gastroenterol. 11, 1251-1266.
43. Takayama, T.K., McMullen, B.A., Nelson, P.S., Matsumura, M., and Fujikawa, K. (2001). Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40, 15341-15348.
44. van der Burg, M.E., Henzen-Logmans, S.C., Berns, E.M., van Putten, W.L., Klijn, J.G., and Foekens, J.A. (1996). Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer 69, 475-479.
45. Whitehouse, C. and Solomon, E. (2003). Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol. Oncol. 88, 152-157.
46. Yousef, G.M. and Diamandis, E.P. (2002). Human tissue kallikreins: a new enzymatic cascade pathway? Biol. Chem. 383, 1045-1057.
47. Yousef, G.M., Kyriakopoulou, L.G., Scorilas, A., Fracchioli, S., Ghiringhello, B., Zarghooni, M., Chang, A., Diamandis, M., Giardina, G., Hartwick, W.J., et al. (2001). Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 61, 7811-7618.
48. Yousef, G.M., Polymeris, M.E., Yacoub, G.M., Scorilas, A., Soosaipillai, A., Popalis, S., Fracchioli, S., Katsaros, D., and Diamandis, E.P. (2003). Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 63, 2223-2227.
49. Yousef, G.M., Obiezu, C.V., Luo, L.Y., Magklara, A., Borgono, C.A., Kishi, T., Memari, N., Michael, I.P., Sidiropoulos, M., Kurlender, L., et al. (2005). Human tissue kallikreins: from gene structure to function and clinical applications. Adv. Clin. Chem. 39, 11-79.
50. Zhang, Z., Barnhill, S.D., Zhang, H., Xu, F., Yu, Y., Jacobs, I., Woolas, R.P., Berchuck, A., Madyastha, K.R., and Bast R.C. Jr. (1999). Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol. Oncol. 73, 56-61.